Satya Das
St Bartholomew's Hospital · 91 works · 5,684 citations · h-index 19
Top works
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
- Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
- Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?
- 177 Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors
- Improving the phenotype risk score as a scalable approach to identifying patients with Mendelian disease
- Immunotherapy After Immunotherapy: Response Rescue in a Patient With Microsatellite Instability-high Colorectal Cancer Post-Pembrolizumab
- The eye of the beholder: orbital metastases from midgut neuroendocrine tumors, a two institution experience
- Promising New Agents for Colorectal Cancer
- Expression of PD-1 and PD-L1 in poorly differentiated neuroendocrine carcinomas of the digestive system: a potential target for anti–PD-1/PD-L1 therapy
- Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy
- Immune checkpoint inhibitors (ICIs) in gastrointestinal (GI) cancer: Immune-related adverse events (IRAEs) and efficacy.
- A multidisciplinary approach to the work up and management of pulmonary carcinoid tumors and DIPNECH: a narrative review
- A phase I study of ATR inhibitor BAY1895344 (elimusertib) plus topotecan (ETCTN 10402): Results of dose escalation.
- Alternative biweekly dosing schedule of trifluridine-tipiracil (TAS-102) reduces rates of myelosuppression while maintaining therapeutic efficacy in patients (pts) with previously treated metastatic colorectal cancer (mCRC).
- Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer
- Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors
- Chemotherapy in Neuroendocrine Tumors
- Carcinoid Heart Disease Management: A Multi-Disciplinary Collaboration
- Hidden Figures: Occult Intra-Cardiac Metastases in Asymptomatic Neuroendocrine Tumor Patients